000022775 001__ 22775
000022775 005__ 20200423203255.0
000022775 0247_ $$2pmid$$apmid:17728549
000022775 0247_ $$2DOI$$a10.1159/000342480
000022775 0247_ $$2Handle$$a2128/11529
000022775 037__ $$aPreJuSER-22775
000022775 041__ $$aeng
000022775 082__ $$a610
000022775 1001_ $$0P:(DE-Juel1)VDB73298$$aGalldiks, N.$$b0$$uFZJ
000022775 245__ $$aDiscrepant MR and [18F]Fluoroethyl-L-Tyrosine PET imaging findings in a patient with bevacizumab failure
000022775 260__ $$aBasel$$bKarger$$c2012
000022775 300__ $$a490 - 494
000022775 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article
000022775 3367_ $$2DataCite$$aOutput Types/Journal article
000022775 3367_ $$00$$2EndNote$$aJournal Article
000022775 3367_ $$2BibTeX$$aARTICLE
000022775 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000022775 3367_ $$2DRIVER$$aarticle
000022775 440_0 $$026503$$aCase Reports in Oncology$$v5
000022775 500__ $$3POF3_Assignment on 2016-02-29
000022775 500__ $$aRecord converted from VDB: 12.11.2012
000022775 520__ $$aPhotodynamic therapy (PDT) has become a well-established treatment for vascular forms of age-related macular degeneration (AMD). The implementation of evidence-based medicine principles into the treatment regimen of AMD seems to be immensly important, since AMD continues to be the most frequent cause of blindness among patients older than 65 years in industrialized countries. Numerous randomized prospective studies demonstrated high levels of evidence for the efficacy of various treatment approaches such as laser photocoagulation, PDT, subretinal surgery or novel anti-angiogenic drugs [Arch Ophthalmol 2006;124:597-599]. The high evidence shown by these studies supported the rationale to use PDT also in additional, less frequent, vasoproliferative diseases. Although these 'case series' and 'individual case control studies' have a low level of evidence, they give us important information for treatment decisions in these rare conditions. The goal of this survey is to review the current literature regarding PDT in vasoproliferative and exudative ocular diseases outside AMD. Many studies modified the treatment parameters of PDT to address the specific pathology of the underlying disease. Table 1 summarizes the diseases and treatment parameters that are described in this part 2, the entire table of this review is included in part 1 (www.karger.com/doi/10.1159/ 000101922).
000022775 536__ $$0G:(DE-Juel1)FUEK409$$2G:(DE-HGF)$$aFunktion und Dysfunktion des Nervensystems$$cP33$$x0
000022775 588__ $$aDataset connected to Pubmed
000022775 650_2 $$2MeSH$$aExudates and Transudates: metabolism
000022775 650_2 $$2MeSH$$aEye Diseases: drug therapy
000022775 650_2 $$2MeSH$$aEye Diseases: metabolism
000022775 650_2 $$2MeSH$$aEye Neoplasms: drug therapy
000022775 650_2 $$2MeSH$$aHumans
000022775 650_2 $$2MeSH$$aNeovascularization, Pathologic: drug therapy
000022775 650_2 $$2MeSH$$aPhotochemotherapy: trends
000022775 7001_ $$0P:(DE-Juel1)VDB101468$$aFilss, C.P.$$b1$$uFZJ
000022775 7001_ $$0P:(DE-HGF)0$$aGoldbrunner, R.$$b2
000022775 7001_ $$0P:(DE-Juel1)131777$$aLangen, K.-J.$$b3$$uFZJ
000022775 773__ $$0PERI:(DE-600)2458961-5$$a10.1159/000342480$$gVol. 5, p. 490 - 494$$p490 - 494$$q5<490 - 494$$tCase reports in oncology$$v5$$x1662-6575$$y2012
000022775 8567_ $$uhttp://dx.doi.org/10.1159/000342480
000022775 8564_ $$uhttps://juser.fz-juelich.de/record/22775/files/342480.pdf$$yOpenAccess
000022775 8564_ $$uhttps://juser.fz-juelich.de/record/22775/files/342480.gif?subformat=icon$$xicon$$yOpenAccess
000022775 8564_ $$uhttps://juser.fz-juelich.de/record/22775/files/342480.jpg?subformat=icon-180$$xicon-180$$yOpenAccess
000022775 8564_ $$uhttps://juser.fz-juelich.de/record/22775/files/342480.jpg?subformat=icon-700$$xicon-700$$yOpenAccess
000022775 8564_ $$uhttps://juser.fz-juelich.de/record/22775/files/342480.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000022775 909CO $$ooai:juser.fz-juelich.de:22775$$pdnbdelivery$$pVDB$$pdriver$$popen_access$$popenaire
000022775 9141_ $$y2012
000022775 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000022775 915__ $$0LIC:(DE-HGF)CCBYNC3$$2HGFVOC$$aCreative Commons Attribution-NonCommercial CC BY-NC 3.0
000022775 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000022775 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000022775 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000022775 915__ $$0StatID:(DE-HGF)0040$$2StatID$$aPeer Review unknown
000022775 9131_ $$0G:(DE-Juel1)FUEK409$$1G:(DE-HGF)POF2-330$$2G:(DE-HGF)POF2-300$$bGesundheit$$kP33$$lFunktion und Dysfunktion des Nervensystems$$vFunktion und Dysfunktion des Nervensystems$$x0
000022775 9132_ $$0G:(DE-HGF)POF3-579H$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vAddenda$$x0
000022775 9201_ $$0I:(DE-Juel1)INM-3-20090406$$gINM$$kINM-3$$lKognitive Neurowissenschaften$$x0
000022775 9201_ $$0I:(DE-Juel1)INM-4-20090406$$gINM$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000022775 970__ $$aVDB:(DE-Juel1)139535
000022775 980__ $$aVDB
000022775 980__ $$aConvertedRecord
000022775 980__ $$ajournal
000022775 980__ $$aI:(DE-Juel1)INM-3-20090406
000022775 980__ $$aI:(DE-Juel1)INM-4-20090406
000022775 980__ $$aUNRESTRICTED
000022775 9801_ $$aFullTexts
000022775 981__ $$aI:(DE-Juel1)INM-4-20090406